Correction to: Efficacy and safety of glecaprevir/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection (Journal of Gastroenterology, (2018), 53, 4, (566-575), 10.1007/s00535-017-1396-0)

Hiromitsu Kumada, Tsunamasa Watanabe, Fumitaka Suzuki, Kenji Ikeda, Ken Sato, Hidenori Toyoda, Masanori Atsukawa, Akio Ido, Akinobu Takaki, Nobuyuki Enomoto, Koji Kato, Katia Alves, Margaret Burroughs, Rebecca Redman, David Pugatch, Tami J. Pilot-Matias, Preethi Krishnan, Rajneet K. Oberoi, Wangang Xie, Kazuaki Chayama

Research output: Contribution to journalComment/debatepeer-review

3 Citations (Scopus)

Abstract

Unfortunately, in the original publication of this article, the copyright line was incorrectly published in PDF as “

Original languageEnglish
Pages (from-to)689
Number of pages1
JournalJournal of Gastroenterology
Volume53
Issue number5
DOIs
Publication statusPublished - May 1 2018

ASJC Scopus subject areas

  • Gastroenterology

Fingerprint Dive into the research topics of 'Correction to: Efficacy and safety of glecaprevir/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection (Journal of Gastroenterology, (2018), 53, 4, (566-575), 10.1007/s00535-017-1396-0)'. Together they form a unique fingerprint.

Cite this